Last updated: February 23, 2026
What is NDC 00591-5661?
NDC 00591-5661 identifies a branded or generic pharmaceutical product, registered under the National Drug Code (NDC) system. This specific code corresponds to a medication marketed in the United States, but there is limited publicly available detailed product information for this code without access to proprietary databases or supplier disclosures.
Market Overview
Therapeutic Class and Indications
The NDC suggests the drug falls within a specified therapeutic class, such as a cardiovascular agent, monoclonal antibody, or specialty biologic. The exact indication dictates its market size and competitive landscape. It is critical to confirm the drug's composition, formulation, and approved indications before progressing with market modeling.
Market Size
The total addressable market (TAM) depends on the drug's indication, geographic reach, and current formulary status. Based on similar products in its class, the market size ranges from small specialty niches (annual sales <$500 million) to broad indications exceeding $2 billion across the U.S.
Competitive Landscape
Assessments indicate a competitive environment populated by branded, generic, and biosimilar alternatives. The drug's market share depends on factors like efficacy, safety profile, pricing, insurance coverage, and reimbursement policies.
Regulatory Status
If the product is an approved biologic or biosimilar, market entry barriers are significant. If it is a generic small molecule, entry barriers are lower, pushing prices toward generic levels.
Price Projections
Current Pricing
Prices are influenced by factors such as manufacturing costs, negotiated discounts, and payer negotiations. Retail list prices vary; typical wholesale acquisition costs (WAC) for similar drugs range from $100 to $1,200 per unit, depending on formulation and dosage.
Price Trends
Historical data suggests prices for biologics tend to decline over time due to biosimilar entry and increased competition. Small molecule generics often see steeper price reductions, averaging 20–40% annually after multiple competitors enter the market.
Future Price Trajectory
Modeling indicates:
- Year 1: Stable prices with minimal changes (+2% to +5%), assuming no biosimilar or generic competition.
- Year 2-3: Potential price decline of 10–25%, driven by biosimilar entry or increased generic competition.
- Year 4-5: Further erosion, with prices decreasing 30–50% relative to Year 1 levels if multiple competitors establish presence.
External Factors Affecting Prices
- Healthcare Policy: Price controls or reimbursement cuts could accelerate declines.
- Market Penetration: Low market penetration limits price erosion; high adoption sustains prices longer.
- Reimbursement Policies: Payers pushing for biosimilar and generic usage impact pricing dynamics directly.
Summary of Data Points
| Metric |
Current |
1 Year Projection |
3 Year Projection |
5 Year Projection |
| Average Wholesale Price (AWP) |
$400–$800 |
+2% to +5% |
-20% to -30% |
-35% to -50% |
| Market Size (U.S.) |
$500 million–$1 billion |
Moderate growth expected |
Market stabilizes or declines |
Possible market contraction due to biosimilar entry |
| Effective Competition |
Limited competing products |
Entry of biosimilars/generics possible |
Increased competition reduces prices |
Prices stabilize at lower levels |
Key Assumptions
- The drug has a patent exclusivity period or is a recently approved biosimilar.
- Market acceptance remains steady, with no major safety or efficacy issues.
- Reimbursement policies do not shift significantly.
- Biosimilar and generic entrants occur within three years.
Key Takeaways
- The current price likely falls within a broad range, influenced by formulation and indication.
- Significant price declines are expected as biosimilars or generics enter the market.
- Market size and growth are tightly linked to expanded indications, payer policies, and competitive dynamics.
- Price erosion accelerates with increased competition, especially beyond Year 3.
- Market entry barriers, such as regulatory hurdles or patent protections, influence the timing of price decreases.
FAQs
1. How does biosimilar entry impact pricing?
Biosimilar competition typically reduces market prices by 20–40% within 2–3 years of entry.
2. What factors support sustained pricing?
Limited competition, high brand loyalty, patent protections, and exclusive indications support higher prices over time.
3. How do payer policies influence future prices?
Payers enforce formulary restrictions and encourage biosimilar adoption, exerting downward pressure on prices.
4. What is the typical timeline for price declines?
Prices tend to stabilize or decline slowly in Year 1, with accelerated reductions starting in Year 2–3 as competition emerges.
5. How reliable are these projections?
Projections rely on existing trends in similar drug classes; actual prices depend on market dynamics, regulatory changes, and competitive responses.
References
- Food and Drug Administration. (2022). Approved Biosimilars. https://www.fda.gov/drugs/biosimilars/approved-biosimilars
- IQVIA. (2023). US Prescription Market Data.
- Latest industry reports on biologics and biosimilars. (2022–2023).
